ARG64903
anti-CDKN2A / p16INK4a antibody
anti-CDKN2A / p16INK4a antibody for Western blot and Human
Chondrogenesis Study antibody
Overview
| Product Description | Goat Polyclonal antibody recognizes CDKN2A / p16INK4a |
|---|---|
| Tested Reactivity | Hu |
| Tested Application | WB |
| Specificity | This antibody is expected to recognize the pancreas isoform (NP_478104.1) only. |
| Host | Goat |
| Clonality | Polyclonal |
| Isotype | IgG |
| Target Name | CDKN2A / p16INK4a |
| Antigen Species | Human |
| Immunogen | C-ILRKKGRLPGEFSE |
| Conjugation | Un-conjugated |
| Alternate Names | Alternative reading frame; CDK4I; P19ARF; P16INK4A; CDKN2; Tumor suppressor ARF; MTS-1; P14; P16; P19; Cyclin-dependent kinase inhibitor 2A; P16INK4; MLM; p14ARF; MTS1; INK4; TP16; P16-INK4A; CMM2; ARF; P14ARF; INK4A |
Application Instructions
| Application Suggestion |
|
||||
|---|---|---|---|---|---|
| Application Note | WB: Recommend incubate at RT for 1h. * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. |
Properties
| Form | Liquid |
|---|---|
| Purification | Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide. |
| Buffer | Tris saline (pH 7.3), 0.02% Sodium azide and 0.5% BSA |
| Preservative | 0.02% Sodium azide |
| Stabilizer | 0.5% BSA |
| Concentration | 0.5 mg/ml |
| Storage Instruction | For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C or below. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. |
| Note | For laboratory research only, not for drug, diagnostic or other use. |
Bioinformation
| Database Links |
Swiss-port # P42771 Human Cyclin-dependent kinase inhibitor 2A |
|---|---|
| Gene Symbol | CDKN2A |
| Gene Full Name | cyclin dependent kinase inhibitor 2A |
| Background | This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, MDM1, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene. [provided by RefSeq, Jul 2008] |
| Function | Acts as a negative regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6. This inhibits their ability to interact with cyclins D and to phosphorylate the retinoblastoma protein. [UniProt] |
| Highlight | Related products: CDKN2A antibodies; CDKN2A Duos / Panels; Anti-Goat IgG secondary antibodies; Related news: Senescence Marker Antibody Panel is launched |
| Research Area | Chondrogenesis Study antibody |
| Calculated MW | 14 kDa |
| PTM | Ubiquitinated in normal cells by TRIP12 via the ubiquitin fusion degradation (UFD) pathway, a process that mediates ubiquitination at the N-terminus, regardeless of the absence of lysine residues. Ubiquitination leads to its proteasomal degradation. In cancer cells, however, TRIP12 is located in a different cell compartment, preventing ubiquitination and degradation. |
